CanBas Co

CanBas Co Enterprise Value

The Enterprise Value (EV) of CanBas Co (4575.T) as of Oct 19, 2026 is 14.17 B JPY. In the previous year, Enterprise Value (EV) was 12.79 B JPY — a change of 10.81% (higher).

Enterprise Value

14.17 BJPY

YoY

10.81%

Last updated:

Enterprise Value (EV) of CanBas Co is 2026 14.17 B JPY. Enterprise Value (EV) of CanBas Co was 2025 12.79 B JPY. It decreases by 10.81% higher compared to the previous year.

The CanBas Co Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2019
14.85 B JPY
Jan 1, 2020
15.25 B JPY
Jan 1, 2021
15.21 B JPY
Jan 1, 2022
15.24 B JPY
Jan 1, 2023
14.00 B JPY
Jan 1, 2024
13.72 B JPY
Jan 1, 2025
12.79 B JPY
Jan 1, 2026
14.17 B JPY
The CanBas Co Enterprise Value history
YEAREnterprise ValueYoY
14.17 BJPY+10.81%
12.79 BJPY-6.84%
13.72 BJPY-1.93%
14.00 BJPY-8.18%
15.24 BJPY+0.23%
15.21 BJPY-0.28%
15.25 BJPY+2.70%
14.85 BJPY-1.96%
15.15 BJPY+2.87%
14.72 BJPY-0.50%
14.80 BJPY+0.48%
14.73 BJPY-3.91%
15.33 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Enterprise Value (EV) of CanBas Co is 14.17 B JPY in 2026.

Enterprise Value (EV) of CanBas Co changed from 12.79 B JPY to 14.17 B JPY, representing a 10.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) CanBas Co since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s JPY, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' JPY varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s CanBas Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — CanBas Co

All Key Metrics — CanBas Co